[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336479-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336479-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","disitamab-vedotin-a-her2-directed-antibody-drug-conjugate-in-patients-with-her2-overexpression-and-her2-low-advanced-breast-cancer-a-phase-iib-study","Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer - a phase I/Ib study","","Disitamab vedotin (DV; RC48-ADC) is an HER2-directed antibody-drug conjugate containing a HER2 antibody, a linker, and monomethyl auristatin E. Preclinical work showed strong antitumor activity across breast, gastric, and ovarian cancer models with varying HER2 expression. This pooled phase I/Ib analysis evaluates safety and efficacy of DV in patients with HER2-overexpression and HER2-low advanced breast cancer, reporting outcomes from dose-escalation and expansion cohorts.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/disitamab-vedotin-a-her2-directed-antibody-drug-conjugate-in-patients-with-her2-overexpression-and-her2-low-advanced-breast-cancer-a-phase-iib-study/336479/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/disitamab-vedotin-a-her2-directed-antibody-drug-conjugate-in-patients-with-her2-overexpression-and-her2-low-advanced-breast-cancer-a-phase-iib-study/336479.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is disitamab vedotin (DV) and what does it target?","Question",{"text":63,"@type":64},"Disitamab vedotin (DV; RC48-ADC) is an antibody-drug conjugate directed at HER2. It includes an HER2-directed antibody, a linker, and monomethyl auristatin E.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was DV administered in the phase I/Ib study?",{"text":68,"@type":64},"In phase I dose escalation, HER2-overexpression advanced breast cancer patients received DV 0.5–2.5 mg/kg once every two weeks (Q2W) until unacceptable toxicity or progressive disease. In phase Ib dose-range/expansion, HER2-overexpression and HER2-low cohorts received their specified Q2W doses, including an RP2D-defined regimen.",{"name":70,"@type":61,"acceptedAnswer":71},"What efficacy and safety outcomes were reported at the recommended phase 2 dose?",{"text":72,"@type":64},"At 2.0 mg/kg RP2D Q2W, confirmed objective response rates and median progression-free survival were reported separately for HER2-overexpression and HER2-low groups. Common (≥5%) grade 3 or higher treatment-emergent adverse events included decreased neutrophil count, increased gamma-glutamyl transferase, asthenia, decreased white blood cell count, peripheral neuropathy, and pain, with a favorable safety profile overall.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336479,1790176334,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","DOI: 10.1002/cac2.12577  \nORIGINAL ARTICLE  \nDisitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study  \nJiayu Wang1 Xiaojia Wang6  \nYunjiang Liu2   Jianmin Fang7  \nQingyuan Zhang3  Yiqun Han1   \n Wei Li4 Binghe Xu1  \nJifeng Feng5  \n1 Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China  \n2 Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China  \n3 Department of Breast Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China  \n4 Department of Medical Oncology, The First Hospital of Jilin University, Changchun, Jilin, P. R. China  \n5 Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, P. R. China  \n6 Department of Breast Medicine, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China  \n7 School of Life Science and Technology, Tongji University, Shanghai, P. R. China  \nCorrespondence  \nBinghe Xu, MD, PhD, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, P. R. China. [Email:](Email: bhxu@hotmail.com)[ bhxu@hotmail.com](Email: bhxu@hotmail.com)  \nTrial registration: NCT02881138 (C001 CNACER); NCT03052634 (C003 CNACER)  \nAbstract  \nBackground: Disitamab vedotin (DV; RC48-ADC) is an antibody-drug conjugate comprising a human epidermal growth factor receptor 2 (HER2)-directed antibody, linker and monomethyl auristatin E. Preclinical studies have shown that DV demonstrated potent antitumor activity in preclinical models of breast, gastric, and ovarian cancers with different levels of HER2 expression. In this pooled analysis, we report the safety and efficacy of DV in patients with HER2-overexpression and HER2-low advanced breast cancer (ABC) .  \nMethods: In the phase I dose-escalation study (C001 CANCER), HER2-overexpression ABC patients received DV at doses of 0.5-2.5 mg/kg once every two weeks (Q2W) until unacceptable toxicity or progressive disease. The dose  \nList of abbreviations: ABC, Advanced breast cancer; ADC, Antibody-drug conjugate; AEs, Adverse events; AUC, Area under the concentration-time curve; CBR, Clinical benefit rate; CI, Confidence interval; Cmax , Peak plasma concentration; CT, Computed tomography; CTCAE, Common Terminology Criteria for Adverse Events; DCR, Disease control rate; DLT, Dose-limiting toxicity; DOR, Duration of response; DV, Disitamab vedotin; ECOG, Eastern Cooperative Oncology Group; FISH, Fluorescence in situ hybridization; HER2, Human epidermal growth factor receptor 2; HR, Hormone receptor; IHC, Immunohistochemistry; ILD, Interstitial lung disease; LVEF, Left ventricular ejection fraction; MRI, Magnetic resonance imaging; MTD, Maximum tolerated dose; MMAE, Microtubule inhibitor monomethyl auristatin E; NCA, Noncompartmental analysis; NCI, National Cancer Institute; ORR, Objective response rate; OS, overall survival; PS, Performance status; AJCC, American Joint Committee on Cancer; TNM, Tumor Node Metastasis; PK, Pharmacokinetics; PD, Progressive disease; PFS, Progression-free survival; Q2W, Every two weeks; Ra (AUC) , Accumulation ratio for AUC; RECIST, Response Evaluation Criteria in Solid Tumors; RP2D, Recommended phase 2 dose; t1/2 , half-life; TAb, Total antibody; T-DXd, Trastuzumab deruxtecan; SG, sacituzumab govitecan; TEAEs, Treatment-emergent adverse events; tmax , time to Cmax ; VC,  \nValine-citrulline; CDK, cyclin-dependent kinase; MBC, Metastatic breast cancer..  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2024 The Author(s) . Cancer Communications pub","cbCaiszNYk5AUysH","https://ap.wps.com/l/cbCaiszNYk5AUysH","pdf",1988574,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Key Words\n# 1 Background","[{\"question\":\"What is disitamab vedotin (DV) and what does it target?\",\"answer\":\"Disitamab vedotin (DV; RC48-ADC) is an antibody-drug conjugate directed at HER2. It includes an HER2-directed antibody, a linker, and monomethyl auristatin E.\"},{\"question\":\"How was DV administered in the phase I/Ib study?\",\"answer\":\"In phase I dose escalation, HER2-overexpression advanced breast cancer patients received DV 0.5–2.5 mg/kg once every two weeks (Q2W) until unacceptable toxicity or progressive disease. In phase Ib dose-range/expansion, HER2-overexpression and HER2-low cohorts received their specified Q2W doses, including an RP2D-defined regimen.\"},{\"question\":\"What efficacy and safety outcomes were reported at the recommended phase 2 dose?\",\"answer\":\"At 2.0 mg/kg RP2D Q2W, confirmed objective response rates and median progression-free survival were reported separately for HER2-overexpression and HER2-low groups. Common (≥5%) grade 3 or higher treatment-emergent adverse events included decreased neutrophil count, increased gamma-glutamyl transferase, asthenia, decreased white blood cell count, peripheral neuropathy, and pain, with a favorable safety profile overall.\"}]","Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer - a phase I/Ib study | PDF",1790015246,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8827700c6566949c0e36bccbbd4b5f55.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c163a69488c2842f737962453cc8349a.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70ba314fc460d83b8a03112ea1c6af6a.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ad04cdbd5f524e09c20a86c59368cee.webp",980,1287]